A5386 - CLINICAL STUDY

RESEARCH SAVES LIVES!

Are you UNDETECTABLE and interested in advancing HIV Research?

UCLA Health | CARE Center
We are looking for HIV+ people who are taking antiretroviral treatment (ART) and whose viral load is undetectable. The goal is to find out if IL-15 is safe alone, or when used in combination with another treatment called broadly neutralizing antibodies (bNAbs). Participants will receive 8 doses of IL-15 given every 3 weeks. Half of the participants will be randomly assigned to also receive the bNAbs with it. After completing these treatments, participants will temporarily stop taking their HIV medicine (ART) and will be evaluated to see how well this treatment controls their viral load.

**BASIC ELIGIBILITY CRITERIA:**

**AGE**
18–65 YEARS OLD

**HIV**
CONTINUOUS HIV TREATMENT
AT LEAST 96wks

**STATUS**
HIV POSITIVE

**VIRAL LOAD**
UNDetectable
AT LEAST 96wks

**COINFECTION**
NO ACTIVE HEPATITIS B OR C INFECTION

**CD4 COUNT**
MORE THAN 500

For more information contact the UCLA study team and ask about the A5386 study at (310) XXX-XXXX or careoutreach@mednet.ucla.edu.